Le Lézard
Classified in: Health
Subjects: SVY, SCZ

Behavioral Screening and Intervention Programs Improve Outcomes and Reduce Costs Among High-Risk Patients, According to New Article in The American Journal of Accountable Care


ALISO VIEJO, Calif., June 20, 2018 /PRNewswire/ -- ConcertoHealth, the leading provider of specialized primary care and supporting clinical services for vulnerable, frail and elderly patients, announced today that The American Journal of Accountable Care has published an article written by ConcertoHealth Southwest Michigan Medical Director Dr. Richard L. Brown, M.D., MPH, on the positive results of evidence-based behavioral screening and intervention (BSI) programs.

ConcertoHealth (PRNewsfoto/ConcertoHealth)

The article, "Lessons Learned in Implementing Behavioral Screening and Intervention," was written to provide primary care practices with key lessons learned from Dr. Brown's vast experience helping primary care settings implement BSI since 2006.

The core components of BSI are smoking screening and cessation; alcohol screening, grief intervention, and referral to treatment; and depression screening and collaborative care. The article reveals that BSI for unhealthy drinking, depression, smoking, and other behavioral risks and disorders improves outcomes and generates substantial cost savings.

Dr. Brown makes several recommendations to improve health outcomes and realize cost savings. Key takeaways from the 11 lessons Dr. Brown offers include:

"At ConcertoHealth, we have seen first-hand the benefits of helping primary care physicians extend the care they provide to their most medically and socially complex patients," said Dr. Brown. "By improving performance on various quality metrics and reducing costs, a robust BSI program could help healthcare providers thrive under value-based care models."

As a full-risk provider that operates exclusively in value-based agreements, ConcertoHealth has BSI programs underway in both Michigan and Washington. The care model provides support for health plans and their networks of primary care providers (PCPs) in caring for their highest-risk patients.

About ConcertoHealth
ConcertoHealth Inc. is the leading provider of specialized primary care and supporting clinical services for vulnerable, frail and elderly patients. ConcertoHealth provides high-touch, individualized care for patients and also deploys wraparound clinical resources to extend the reach of primary care providers. Operating exclusively in value-based agreements, the ConcertoHealth care model, elevated by Patient3D, improves overall health quality and outcomes for high-need patient populations. The ConcertoHealth care model is proven to reduce admissions by 30.3 percent and readmissions by 17.1 percent, benefitting patients, payers and their provider networks alike. The company is headquartered in Aliso Viejo, Calif.

www.concertohealth.com

 

SOURCE ConcertoHealth


These press releases may also interest you

at 06:31
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual...

at 06:30
Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular...

at 06:30
The collagen water market is booming thanks to the growing popularity of health and beauty products. Consumers are more interested in skincare and healthy eating, which is driving manufacturers to create collagen-infused drinks and cosmetics. A new...

at 06:30
Viavi Solutions Inc. (VIAVI)  today announced it has participated in the 2024 RIC Forum, March 26-28, in Dallas, Texas. The company contributed its TeraVM RIC Test and TM500 Network Tester to multiple demonstrations, building on collaborations at MWC...

at 06:30
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points  New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively...

at 06:30
The "PCR Markets. Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027" report has been added to...



News published on and distributed by: